NCT04481113View on ClinicalTrials.gov

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

October 11, 2023

Study Completion Date

December 30, 2025

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8HER2 Negative Breast AdenocarcinomaHormone Receptor Positive Breast AdenocarcinomaInvasive Breast CarcinomaMultifocal Breast CarcinomaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Unilateral Breast Carcinoma
Interventions
DRUG

Abemaciclib

Given PO

DRUG

Niraparib Tosylate Monohydrate

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER